Immatics (IMTX) Non-Current Assets (2019 - 2025)
Immatics (IMTX) reported Non-Current Assets of $67.9 million for Q4 2025, down 4.58% on a YoY basis from $71.2 million in Q4 2024, and down 4.06% sequentially from $70.8 million in Q3 2025.
Immatics (IMTX) Non-Current Assets (2019 - 2025) Analysis & Trends
Immatics (IMTX) has 7 years of Non-Current Assets data on file, last reported at $67.9 million in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Assets fell 4.58% year-over-year to $67.9 million; the trailing twelve-month figure through Dec 2025 stood at $67.9 million (down 4.58% YoY), and the FY2025 full-year result was $65.9 million, down 8.57% from the prior year.
- Non-Current Assets eased to $67.9 million in Q4 2025, from $70.8 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $73.1 million in Q2 2024 to a low of $19.0 million in Q1 2021.
- A 5-year average of $49.3 million and a median of $53.4 million in 2023 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets jumped 108.38% in 2023 and slipped 4.58% in 2025, its largest moves.
- Tracing IMTX's Non-Current Assets over 5 years: stood at $25.7 million in 2021, then gained by 21.88% to $31.3 million in 2022, then jumped by 108.38% to $65.2 million in 2023, then advanced by 9.15% to $71.2 million in 2024, then retreated by 4.58% to $67.9 million in 2025.
- Business Quant data shows IMTX's Non-Current Assets at $67.9 million in Q4 2025, $70.8 million in Q3 2025, and $71.7 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 5.83 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 30.30 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.95 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 285.82 Mn |
| 10 | Immatics | 1.11 Bn | 1.11 Bn | - | 67.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 67.90 Mn |
| Sep 30, 2025 | 70.77 Mn |
| Jun 30, 2025 | 71.73 Mn |
| Mar 31, 2025 | 71.66 Mn |
| Dec 31, 2024 | 71.16 Mn |
| Sep 30, 2024 | 70.79 Mn |
| Jun 30, 2024 | 73.07 Mn |
| Mar 31, 2024 | 70.32 Mn |
| Dec 31, 2023 | 65.20 Mn |
| Sep 30, 2023 | 57.09 Mn |
| Jun 30, 2023 | 49.62 Mn |
| Mar 31, 2023 | 35.89 Mn |
| Dec 31, 2022 | 31.29 Mn |
| Sep 30, 2022 | 32.25 Mn |
| Jun 30, 2022 | 34.44 Mn |
| Mar 31, 2022 | 24.99 Mn |
| Dec 31, 2021 | 25.67 Mn |
| Sep 30, 2021 | 22.14 Mn |
| Jun 30, 2021 | 21.88 Mn |
| Mar 31, 2021 | 19.03 Mn |